{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:12:57Z","timestamp":1768594377570,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ccl.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:39:11Z","timestamp":1566927551000},"page":"407-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Trastuzumab-Induced Cardiomyopathy"],"prefix":"10.1016","volume":"37","author":[{"given":"Rachel","family":"Barish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Gates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2019.07.005_bib1","first-page":"428062","article-title":"Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer","volume":"2012","author":"Nahta","year":"2012","journal-title":"ISRN Oncol"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.005_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.005_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"issue":"5S","key":"10.1016\/j.ccl.2019.07.005_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.6004\/jnccn.2018.0043","article-title":"NCCN guidelines updates: breast cancer","volume":"16","author":"Giordano","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.005_bib5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.ccl.2019.07.005_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ccl.2019.07.005_bib7","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.ccl.2019.07.005_bib8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2016.67.0182","volume":"34","author":"Denduluri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.005_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0092-8674(82)90065-4","article-title":"Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas","volume":"28","author":"Padhy","year":"1982","journal-title":"Cell"},{"issue":"4785","key":"10.1016\/j.ccl.2019.07.005_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.005_bib11","doi-asserted-by":"crossref","first-page":"7675","DOI":"10.1007\/s13277-015-4649-7","article-title":"The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients","volume":"37","author":"Zhu","year":"2016","journal-title":"Tumour Biol"},{"issue":"13","key":"10.1016\/j.ccl.2019.07.005_bib12","first-page":"2825","article-title":"Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts","volume":"58","author":"Baselga","year":"1998","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","article-title":"Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer","volume":"149","author":"Yu","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"9742","key":"10.1016\/j.ccl.2019.07.005_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1758834012469429","article-title":"Gastric cancer and trastuzumab: first biologic therapy in gastric cancer","volume":"5","author":"Gunturu","year":"2013","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.005_bib18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ccl.2019.07.005_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2019.07.005_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2019.07.005_bib21","series-title":"FDA approves Genentech's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment [press release]","year":"2019"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.005_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-019-1115-2","article-title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","volume":"21","author":"Chia","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.ccl.2019.07.005_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3816\/CBC.2004.n.033","article-title":"Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer","volume":"5","author":"Tripathy","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ccl.2019.07.005_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv301","article-title":"The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study","volume":"108","author":"Goldhar","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6555","key":"10.1016\/j.ccl.2019.07.005_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2019.07.005_bib26","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1007\/s12032-010-9717-7","article-title":"Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005","volume":"28","author":"Du","year":"2011","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.005_bib27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.echo.2014.01.014","article-title":"Doxorubicin and trastuzumab regimen induces biventricular failure in mice","volume":"27","author":"Milano","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"21","key":"10.1016\/j.ccl.2019.07.005_bib28","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in breast cancer patients","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccl.2019.07.005_bib29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib30","doi-asserted-by":"crossref","first-page":"H660","DOI":"10.1152\/ajpheart.00268.2005","article-title":"Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure","volume":"289","author":"Liu","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"22","key":"10.1016\/j.ccl.2019.07.005_bib31","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","article-title":"ERBB2 inhibition and heart failure","volume":"367","author":"Cote","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.ccl.2019.07.005_bib32","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.005_bib33","series-title":"Type I and type II cardiomyopathy classifications are complete Nonsense: PRO. American College of Cardiology. Latest in cardiology Web site","author":"Witteles","year":"2018"},{"issue":"24","key":"10.1016\/j.ccl.2019.07.005_bib34","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.005_bib35","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","article-title":"Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter","volume":"34","author":"Dang","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.ccl.2019.07.005_bib36","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"10075","key":"10.1016\/j.ccl.2019.07.005_bib37","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"33","key":"10.1016\/j.ccl.2019.07.005_bib38","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.ccl.2019.07.005_bib39","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1200\/JCO.2017.74.1165","volume":"35","author":"Ganz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ccl.2019.07.005_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1477-7800-5-9","article-title":"The role of Herceptin in early breast cancer","volume":"5","author":"Subramanian","year":"2008","journal-title":"Int Semin Surg Oncol"},{"key":"10.1016\/j.ccl.2019.07.005_bib41","doi-asserted-by":"crossref","unstructured":"Slamon D, Eirmann W, Robert N, et\u00a0al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC\u2192T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC\u2192TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Proceedings of the\u00a038th Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, December 8-12, 2015. Philadelphia (PA). AACR, 2016.","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"issue":"2","key":"10.1016\/j.ccl.2019.07.005_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2017.08.024","article-title":"Left ventricular dysfunction in cancer treatment: is it relevant?","volume":"6","author":"Kenigsberg","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.ccl.2019.07.005_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of\u00a0adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.ccl.2019.07.005_bib44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"issue":"25 Pt A","key":"10.1016\/j.ccl.2019.07.005_bib45","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.005_bib46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","article-title":"Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial","volume":"11","author":"Negishi","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.005_bib47","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jcmg.2018.05.011","article-title":"Optimal treatment of stage B heart failure in cardio-oncology?: the promise of strain","volume":"11","author":"Barac","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"36","key":"10.1016\/j.ccl.2019.07.005_bib48","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehw359","article-title":"An ESC position paper on cardio-oncology","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ccl.2019.07.005_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/heartjnl-2015-307894","article-title":"Roadmap for biomarkers of cancer therapy cardiotoxicity","volume":"102","author":"Yu","year":"2016","journal-title":"Heart"},{"issue":"25","key":"10.1016\/j.ccl.2019.07.005_bib50","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.ccl.2019.07.005_bib51","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2019.07.005_bib52","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.ccl.2019.07.005_bib53","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ccl.2019.07.005_bib54","article-title":"Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (prevention of cardiac dysfunction during adjuvant breast cancer therapy) study","volume":"6","author":"Gulati","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.005_bib55","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to novel therapies in cardio-oncology research (MANTICORE 101-breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ccl.2019.07.005_bib56","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"issue":"16","key":"10.1016\/j.ccl.2019.07.005_bib57","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865119300542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:51:50Z","timestamp":1760007110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865119300542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0733865119300542"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab-Induced Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}